Neutrophil specific granule deficiency (SGD) is a rare congenital disorder marked by recurrent bacterial infections. Neutrophils from SGD patients lack secondary and tertiary granules and their content proteins and lack normal neutrophil functions. Gene inactivating mutations in the C/EBPε gene have been identified in two SGD patients. Our studies on a third SGD patient revealed a heterozygous mutation in the C/EBPε gene.
INTRODUCTION
The generation of mature neutrophils in the peripheral blood of adult mammals is a highly regulated process that is initiated in the bone marrow (rev in 1 ) . As the developing neutrophil makes the transition from the promyelocyte to the myelocyte stage, it acquires secondary ("specific") granules and their content proteins (rev in [2] [3] [4] ), a process that is dependent on the interplay of a number of lineage-specific transcription factors (rev in [5] [6] [7] [8] ). Specific granules contain four major proteins, namely, transcobalamin 1 (TC1), lactoferrin (LF), human neutrophil collagenase (HNC) and human neutrophil gelatinase (HNG), and their acquisition provides a unique marker of commitment to terminal neutrophil differentiation (rev in 2, 3 ). Several lines of evidence from our laboratory have established that the expression of the secondary granule protein (SGP) genes, which are functionally diverse and physically unlinked, is coordinately regulated at the level of mRNA transcription (rev in 2, 3 ). Absence of SGP expression is a consistent abnormality in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and in neutrophil specific granule deficiency (SGD), all disorders associated with disruption of the more distal events of the neutrophil maturation program. SGD is a rare congenital disorder thought to be inherited in an autosomal recessive manner. Neutrophils from affected individuals display atypical pseudo-PelgerHuet type bilobed nuclei, and lack secondary and tertiary granules and their content proteins. Additional defects in neutrophil function including abnormal chemotaxis, respiratory burst and receptor upregulation are also observed. As a result of these combined abnormalities, SGD patients are prone to bacterial infections 9, 10 .
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Mutations in the CCAAT enhancer binding protein epsilon (C/EBPε) gene that result in absent C/EBPε protein expression have been found in two cases of SGD, and are thought to be responsible for the disease in those patients 11, 12 . C/EBPε belongs to a family of basic region leucine zipper (b/Zip) proteins which bind the consensus DNA sequence 5'TKNNGYAAK3' (Y=C or T, K=T or G) within the regulatory regions of target genes as homo-or hetero-dimers (rev in 13 ). Interestingly, neutrophils from C/EBPε-/-mice have morphological and biochemical features very similar to those observed in patients with SGD, including absent neutrophil and eosinophil secondary and tertiary granules and their content proteins, defects in respiratory burst, chemotaxis and bactericidal activity, and atypical bilobed nuclei 14 . Sequence analysis of the C/EBPε locus of our SGD patient was recently performed in our laboratory. We have identified a heterozygous Valine to Alanine mutation at amino acid 218 in the basic region of the C/EBPε gene. However, this mutation does not diminish the transactivation capability of the mutant C/EBPε in transient transfection assays. Our observations suggest that this structural abnormality in the C/EBPε gene likely contributes to the lesion underlying SGD since it is incapable of synergistically activating SGP gene expression in concert with the Gfi-1 transcription factor, which itself is essential for SGP expression..
MATERIALS AND METHODS
IRB approval was obtained from both the University of Michigan and Yale University for collecting blood and bone marrow on this patient.
Patient information and isolation of bone marrow:
The SGD patient has been previously described 9, 15 . Briefly, the patient is a 47 year-old man with no evidence of
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From infection at the time of this study. Following informed consent, bone marrow was isolated from the patient, and showed normal cellularity comparable to his previous marrows 9, 15 . Normal bone marrow was obtained from anonymous discarded samples.
Isolation of peripheral blood neutrophils from normal individuals and the SGD patient: Whole blood samples were obtained from the SGD patient and from healthy volunteers following guidelines for informed consent set by the University of Michigan School of Medicine Committee on the Use of Human Subjects in Research. Neutrophils were isolated as previously described 16 . Since the SGD PMNs lack secondary granules, the buoyant density of the diseased PMNs is altered. Therefore, to isolate neutrophils efficiently, the specific gravity of the Ficoll-Paque had to be adjusted to 1.066.
PCR amplification and sequencing of the C/EBPε gene from the SGD patient:
Genomic DNA was obtained from the peripheral blood neutrophils of the SGD patient and from normal donors using the TriZol method (Invitrogen). Genomic DNA was PCR amplified using Platinum Taq DNA polymerase (Life Technologies) per manufacturer's instructions and cycled as follows: 96°C for 12 min, followed by a three-step cycle 94°C for 30 s, 60°C for 30 s, and 72°C for 2 min for 35-40 cycles. PCR products were purified and recovered using PCR purification columns (Qiagen). The products were sequenced with an ABI Prism Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Corp). Primers were based on published sequence available from EMBL/GenBank/DDBJ under accession no.U48865, as previously described 17 . A mutation identified at aa 218 converting a Valine to an Alanine residue was introduced into pCDNA3.1 C/EBPε using the QuickChange protocol (Stratagene), using the City, UT) Thousand Oaks, CA) and NB4 cells were all grown as previously described [18] [19] [20] . All cells were maintained at 37ºC in a humidified 5% CO 2 incubator. 32Dwt18 cells were transiently transfected as previously described, using 10µg of the wild type or Gfi-1 mutant, generated by Quik-Change (Stratagene, Cedar Creek, TX) (resulting in a mutant Gfi-1 site 5' TAGCAGC 3') reporter HNC plasmid and 2µg pCMVβgal (Clontech, Palo Alto, CA), an internal control plasmid used to monitor transfection efficiency as previously described 21 . Transfected cells were incubated at 37ºC in 5% CO 2 for [16] [17] [18] [19] [20] hours. 293T cells were transfected using FuGene (Roche Applied Sciences) according to the manufacturer's protocol. Luciferase activity was then determined using an assay kit from Promega Biotech (Madison, WI) as per manufacturer's instructions. Co-transfection experiments included 10µg of pCMV-C/EBPε 32 , or a Gfi-1 expression plasmid (a gift from Dr. M. Horwitz, University of Washington, Seattle, WA). Luciferase expression levels were normalized to the levels of β-galactosidase expression 21 .
Generation of EML (Erythroid Myeloid Lymphoid) cells line from Gfi-1+/-and Gfi-1+/+ bone marrow:
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From An EML cell line was generated from the bone marrow of mice deficient for the Gfi-1 gene using methodology previously described 22 . Briefly, Gfi-1 +/-mice and wild type littermates were injected with 5-fluorouracil (5-FU, 100mg/kg). Whole bone marrow was harvested 3-5 days later and cultured for 48 hours in IMDM supplemented with 20%
(vol/vol) horse serum, murine GM-CSF (2.5ng/ml, Immunex, Thousand Oaks, CA), human IL-6 (20ng/ml, Peprotech, Rocky Hill, NJ), and murine IL-1b (10ng/ml, Peprotech, Rocky Hill, NJ ). The cells were transduced with a truncated retinoic acid receptor alpha (RARα403) by spinfection using supernatants derived from a stable GP+E86 producer line. Spinfections were performed over 2 hours with the addition of polybrene (4 µ g/ml). Following spinfection the cells were transferred to IMDM supplemented with 20% horse serum, rat SCF (200ng/ml, Peprotech), Wehi-3B conditioned medium (0.25%) as a source of IL-3 (2.5-5ng/ml, Peprotech, Rocky Hill, NJ) and human erythropoietin (8U/ml, Amgen, Thousand Oaks, CA). Transduced cells were passaged every 2 to 3 days in IMDM medium supplemented with 20% (vol/vol) horse serum and 15% BHK-MKL conditioned medium as a source of SCF. The cells were exposed to G418 for an initial period of 10 days. Within 1 to 2 months rapidly proliferating cell lines were generated. The genotype of the resulting Gfi1+/-EML and Gfi-1+/+ cells was confirmed by PCR analysis using previously described oligonucleotide primers 23 (data not shown).
Induction of Gfi-1+/-and +/+ EML cells:
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From EML cells were induced sequentially to mature neutrophils via the promyelocytic stage (EPRO cells) using 10µM ATRA as previously described 22, 24 . Cultures were harvested at the indicated times for RNA and whole cell protein extract preparation.
Flow Cytometry:
Gfi-1+/-and +/+ EML cells were stained and analyzed using a 
Preparation of nuclear extracts:
All nuclear extracts were prepared as described previously 21 .
Oligonucleotide pulldown assay: This assay was conducted as previously documented 25 using 20µg of biotinylated C/EBP/Gfi1 oligomers:
5'CATTATAAATTGCAAAACTGTCAGAGTG 3'. The DNA-protein complexes were C/EBPε is expressed in the bone marrow and peripheral blood neutrophils of our SGD patient: Since the heterozygous V218A mutation in the C/EBPε gene from the SGD patient did not impair transactivation of SGP reporter genes, we examined whether this substitution had an effect on C/EBPε expression at the RNA or protein level. We evaluated C/EBPε expression by both real-time PCR and western blot analysis. Real-time PCR using cDNA prepared from SGD and normal control PMN RNA was performed using oligomers specific for C/EBPε. The expression of C/EBPε was normalized to that of β-actin and expressed as a fold increase over the normal control. As shown in Figure   3A , the C/EBPε transcript was expressed at 19 fold higher levels as compared to the normal control. Western blot analysis revealed that this increase in expression was also reflected at the protein level, with higher levels of C/EBPε protein in the SGD PMNs (lane 4) served as a positive control. These observations confirm that the V218A C/EBPε mutation does not cause the protein to be unstable. In fact, we cannot rule out the possibility that it may actually be more stable than its wild type counterpart.
Microarray analysis of SGD versus normal bone marrow reveals the upregulation of the transcription factor PU.1 and its target genes:
Since the V218A C/EBPε mutation did not appear to account for the SGD phenotype in our patient, we sought to identify other potential candidate factors to explain his disease. We performed microarray analysis on RNA isolated from the bone marrow of the patient and from a healthy volunteer using the human Affymetrix U133 set (900370) gene chip representing 22,000 genes or ORFs and 22,000 ESTs. A total of 4393 differentially regulated genes were identified. We identified several genes on the list that have been previously demonstrated to be involved in neutrophil development and/or function (Table 1) .
Our laboratory has previously reported reduced expression of the primary granule proteins defensin alpha1 and 4 as well as the secondary granule proteins neutrophil collagenase (HNC), neutrophil gelatinase (HNG) and transcobalamin 1 (TC1) in this SGD patient at the RNA level 15 . Our microarray analysis (Table 1) corroborates this observation. Furthermore, the presence of a downregulated eosinophil specific transcript (eosinophil cationic protein, -4.8) was also confirmatory, since SGD patients lack both neutrophil and eosinophil secondary granules (rev in 28 ). Additionally, a number of proteins involved in neutrophil function were also found to be dysregulated in SGD (Table 1 ).
The SGD bone marrow also showed abnormal expression of a number of transcription factors (Table 1) . Interestingly, several members of the C/EBP family, including C/EBPα, C/EBPδ and C/EBPε were all expressed at slightly higher levels (1.5-2.1 fold) in the SGD bone marrow as compared to the control. Additionally, levels of PU.1 were upregulated (3.2 fold) in the SGD bone marrow. PU.1 belongs to the Ets family of transcription factors and plays a vital role in B cell, macrophage and late neutrophil development 29, 30 . PU.1-/-mice have markedly impaired neutrophil production, with an abnormal pattern of neutrophil-specific gene expression, absence of secondary and tertiary granules and functional impairment with defects in respiratory burst and phagocytosis. 31, 32 . In the face of its altered expression in the SGD patient, we examined the PU.1 gene for mutations. Thorough examination of all exons and exonintron boundaries of the PU.1 gene by direct sequencing of PCR products revealed no mutations (data not shown). However, we observed that expression of a number of PU.1 regulated genes was also upregulated in the SGD bone marrow (Table 1 , marked in gray).
These include Egr1 (early growth response 1) a transcription factor that plays an important role in macrophage differentiation (see 33 ); CD11b (Integrin αM) and CD18
(mac-1 β subunit), both members of the integrin family of cell surface markers;
Proteinase 3 and Bactericidal permeability-increasing protein (BPI), both primary granule proteins; gp91 phox , also known as cytochrome b-245 b polypeptide (CYBB) and gp47 phox or NCF1, both of which contribute to the NADPH-reductase complex associated with the respiratory burst activity of normal neutrophils (see 7 and references within).
PU.1 RNA and protein levels are upregulated in SGD PMNs and bear a reciprocal relationship to that of Growth factor independence-1 (Gfi-1)
We confirmed increased expression of PU.1 in SGD PMNs by real-time PCR using cDNA prepared from SGD and normal control PMN RNAs. The expression of PU.1 was normalized to that of β-actin and expressed as a percentage of control (100%).
As shown in Figure 4A , PU.1 expression in SGD PMNs was 25-fold higher than in normal PMNs, confirming an even higher level of upregulation than was suggested by microarray analysis (Table 1 ). Increased PU.1 mRNA suggests transcriptional upregulation of the PU.1 promoter, perhaps through disrupted binding of a negative regulator. Such a negative regulator has recently been described. In a recent study, Hock et al described mice nullizygous for the zinc finger containing transcription factor Gfi-1
(Growth factor independence-1) 23 , which bear striking similarities to the C/EBPε knockout mice and to patients with SGD. Gfi-1-/-mice lack secondary and tertiary granule protein gene expression despite C/EBPε expression 23 . Furthermore, these mice express elevated levels of PU.1 and its downstream target genes including the M-CSF receptor 23 . Gfi-1 has been described as a negative regulator of gene expression in T lymphocytes (rev. in [34] [35] [36] ). Since the expression of Gfi-1 and PU.1 has been reported to have a reciprocal relationship, we examined levels of Gfi-1 in SGD PMNs by real-time detection PCR. Significantly decreased levels of Gfi-1 RNA were observed in our SGD patient (7%) compared to the normal control (100%) ( Figure 4A ).
We next examined Gfi-1 and PU.1 protein levels by western blot analysis. Figure   4B demonstrates markedly reduced levels of Gfi-1 protein in the SGD PMN sample compared to two normal controls. In contrast, PU.1 levels were significantly higher in the SGD patient than in the two control PMN samples. Equal loading of protein in each lane was confirmed by stripping the blot and probing with a β−actin antibody.
Gfi-1+/-EML cell line shares morphologic and biochemical features of the Gfi-1 null and SGD patient bone marrow:
For
is extremely rare, and obtaining adequate patient samples is difficult. Therefore, we established a cell line model in which levels of Gfi-1 are significantly reduced while C/EBPε levels remain normal to high. We harvested bone marrow from 5-FU treated Gfi-1+/-mice and age-matched wild type littermates, and transduced them with a truncated retinoic acid receptor alpha (RARα403) as previously described 22, 24 . Within 1 to 2 months, rapidly proliferating factor dependent cell lines emerged. We confirmed the genotype of the Gfi1+/-and +/+ EML cells using a previously described PCR approach (data not shown).
Analysis of the cell surface markers on the EML Gfi1+/+ and +/-cells revealed clear differences ( Figure 5A ). The expression of Sca-1 (hematopoietic stem cell marker), With the exception of c-kit, this general expression pattern followed the same trend as that observed for bone marrow myeloid progenitors of Gfi-1 null mice 23 . Furthermore, induction of EML Gfi-1+/+ and +/-cells with ATRA and IL-3 (3 days) followed by GM-CSF induction gave rise to EPRO (EML-derived Promyelocytes) cells. Wright-Giemsa staining ( Figure 5B ) of Gfi-1+/-cells revealed abnormal ring-shaped EPRO cells, while EML Gfi-1+/+ cells yielded promyelocytes with normal morphology. These abnormal cells have been described previously in the bone marrow of Gfi-1-/-mice 23 . Further maturation of the EPRO cells with ATRA gave rise to neutrophils with fewer nuclear lobes and a more monocyte/macrophage-like cytoplasm as compared to the equivalent wild type cells ( Figure 5B ). Interestingly, we failed in two attempts to isolate EML cells from Gfi-1-/-bone marrow. In two recent studies, Gfi-1 has been shown to restrict proliferation and maintain quiescence of hematopoietic stem cells (rev. in 36 ). We hypothesize that complete loss of Gfi-1 activity may increase cycling of the stem cell progenitors, which in turn may compromise the ability to transduce an early progenitor cell, an essential step in the process of generating EML cells.
Gfi-1+/-EPRO cells express higher levels of C/EBPε and PU.1 and reduced levels of SGP genes:
Gfi-1+/-and +/+ EPRO cells were induced to terminally differentiate by the addition of ATRA. RNA and total cellular proteins were harvested at 24 hour intervals. Despite adequate levels of both C/EBPε (Figure 3 ) and PU.1 ( Figure 4A and B) in the SGD PMNs, both essential factors for neutrophil secondary and tertiary granule protein gene expression, no expression of the SGP genes was observed in the patient 15 . We 
Gfi-1 and C/EBPε both bind the HNC promoter:
In order to validate the role of Gfi-1 in directly activating the HNC promoter we performed an oligonucleotide pulldown assay to demonstrate binding of this factor to the Gfi-1 site in the HNC promoter. Nuclear extracts prepared from uninduced and ATRAinduced MPRO cells, a model for neutrophil maturation, were incubated with biotinylated oligomers representing the Gfi-1/C/EBP I site in the HNC promoter ( Figure   8A ). The DNA-protein complexes were recovered using streptavidin-agarose beads and the bound proteins resolved by SDS-PAGE and western blot analysis. As shown in (Fig 8C) . 19 ,20
DISCUSSION
We have described a patient with the rare congenital disorder SGD. SGD is typically associated with inactivating mutations in the C/EBPε gene. DNA sequence analysis in our patient revealed a heterozygous substitution at amino acid 218 (NM_001805) that lies within the highly conserved DNA-binding basic region of the C/EBPε gene. This results in the substitution of a valine to an alanine at this position. We introduced this mutation into wild type C/EBPε and evaluated the ability of the mutant gene to transactivate SGP reporter genes (HNC and LF). We showed that the mutant C/EBPε transactivated the SGP promoters with equal efficiency as the wild type, suggesting that the mutation is unlikely to alter C/EBPε mediated SGP gene expression in the SGD patient. Given that the mutation occurs in the basic region of C/EBPε , coinciding with the region harboring the nuclear localization signal of bZip proteins, we examined whether this substitution altered the ability of C/EBPε to localize to the nucleus. In preliminary transient transfection, immunofluorescence studies we showed that the V218AC/EBPε protein does not accumulate in the cytoplasm (AK-G, HS and NB, unpublished observations), thus suggesting that mislocalization of the mutant C/EBPε protein is unlikely to explain the SGD phenotype. Microarray analysis revealed dysregulated expression of several transcription factors, among which were C/EBPε and PU.1. Both these factors were upregulated at the protein and RNA levels in the SGD bone marrow. The increased expression of C/EBPε and PU.1, both critical for normal development of neutrophils (rev in 7 ), strongly suggested decreased activity of a negative regulator of both factors. The Gfi-1 (Growth factor independence-1) gene encodes a nuclear protein with six carboxy terminal zincfinger domains and a novel, highly conserved N-terminal domain of 20 amino acids termed the SNAG domain, which is thought to confer negative regulatory properties on
Gfi-1 (rev in 34, 39 ). Gfi-1-null mice, as described by Hock et al, 23 have defects similar to those in C/EBPε knockout mice and patients with SGD. Mice lacking Gfi-1 are severely neutropenic and eventually succumb to bacterial infections. Much like our SGD patient where Gfi-1 levels are significantly reduced, Gfi-1 null mice lack secondary and tertiary granule protein gene expression despite C/EBPε expression 23 .
In an attempt to design an in vitro model for Gfi-1 lo SGD, we used bone marrow from Gfi-1 wild type and heterozygous mice to generate factor-dependent EML cell lines that can terminally differentiate into mature neutrophils. The Gfi-1 heterozygous mice were previously reported to have normal life spans and have therefore not been described in detail Gfi-1 null mice leads to loss of SGP expression 23 , it is tempting to speculate that the defect in our SGD patient results in a hypomorphic Gfi-1 allele leading to lower than heterozygous levels of Gfi-1 , which in turn contributes to loss of SGP expression. Why the levels of Gfi-1 are diminished in the SGD patient is a question currently under study in our laboratory.
Heterozygous dominant negative mutations in the Gfi-1 gene have been described in two patients with severe congenital neutropenia (SCN) 41 underscoring the role of Gfi-1 in the neutrophil maturation pathway. These observations led us to hypothesize that both C/EBPε and Gfi-1 are required for secondary and tertiary granule protein gene expression in the developing neutrophil. However, our SGD patient is not neutropenic; an observation that may be explained by the fact that Gfi-1 levels in this patient are significantly reduced, but not completely absent.
Gfi-1 is a negative regulator of gene expression in T lymphocytes and can affect target promoters differentially according to the cellular and promoter context (rev in 34 ).
Recent chromatin immunoprecipitation 42 studies and analysis of the Gfi-1 null mice 23 demonstrate that Gfi-1 negatively regulates PU.1 and C/EBPε expression in myeloid cells. Gfi-1 has not been frequently described as a transactivator. In one study, Gfi-1 and its paralog Gfi-1B activated transcription of a promoter containing four copies of their consensus-binding site in an erythroid cell line 43 . We demonstrate for the first time that
Gfi-1 acts to upregulate neutrophil collagenase (MMP-8) promoter activity in myeloid cells. Additionally, we show that together with WT C/EBPε, Gfi-1 synergistically activates the HNC promoter during myeloid differentiation.
We hypothesize that decreased levels of Gfi-1 in the SGD bone marrow prevent the upregulation of the SGP genes by two mechanisms. First, decreased levels of Gfi-1 are insufficient to provide synergistic cooperation with mutant C/EBPε to transactivate the SGP gene promoters. Second, in light of a recent report by Laslo et al 33 , increased PU.1 levels result in the upregulation of the zinc-finger containing Egr-1 transcription factor ( also upregulated in our SGD patient, see Table 1 ), which in turn binds to the Gfi-1 promoter and blocks its expression. Diminished Gfi-1 levels then contribute to decreased SGP expression in the SGD patient.
It is possible that the heterozygous C/EBPε gene mutation observed in our SGD patient, may in fact be responsible for the observed decrease in Gfi-1 levels in this patient. This possibility is currently being tested in our laboratory.
In summary, we have demonstrated that in an SGD patient with a V218A heterozygous mutation in C/EBPε , an imbalance in the expression of myeloid-specific transcription factors leads to developmental and functional neutrophils abnormalities.
Efforts are currently underway to delineate the mechanism underlying the disruption of the neutrophil development pathway in this C/EBPε positive Gfi-1 lo SGD patient.
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